Fly News Breaks for March 4, 2020
Mar 4, 2020 | 07:51 EDT
Wedbush analyst Laura Chico lowered the firm's price target on Voyager Therapeutics (VYGR) to $27 from $34 as she extends her VY-HTT01 launch timing by a year. The analyst notes that Voyager Therapeutics and partner Neurocrine (NBIX) will increase RESTORE total enrollment and shift to a 2:1 randomization scheme for the Parkinson's disease gene therapy study. Overall, she awaits additional updates on timing for enrollment completion, but sees modifications likely facilitating recruitment. Chico keeps an Outperform rating on Voyager's shares.
News For VYGR;NBIX From the Last 2 Days
There are no results for your query VYGR;NBIX